Clinical trials
Atherosclerosis trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 9 |
| Recruiting | 3 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Xuanwu Hospital, Beijing | 6 |
| Boston Scientific Corporation | 2 |
| Sun Yat-sen University | 2 |
| Amgen | 1 |
| Beijing Anzhen Hospital | 1 |
| C. R. Bard | 1 |
| China National Center for Cardiovascular Diseases | 1 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| Chinese University of Hong Kong | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atherosclerosis | 27 |
| Ischemia | 5 |
| Coronary Artery Disease | 2 |
| Coronary Disease | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Acute Coronary Syndrome | 1 |
| Arthritis, Psoriatic | 1 |
| Cardiovascular Diseases | 1 |
| Constriction, Pathologic | 1 |
| Diabetes Mellitus, Type 2 | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.